Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Stanford University

Status

Completed

Conditions

Carcinoma, Renal Cell

Kidney Neoplasms

Kidney (Renal Cell) Cancer

Treatments

Procedure: FDG PET CT

Drug: Gadolinium-DTPA

Drug: F-18 Fluoro-deoxi-glucose

Procedure: DCE MRI

Drug: Sunitinib

Study type

Interventional

Funder types

Other

NETWORK

Identifiers

NCT00537056

IRB-08558

97807 (Other Identifier)

RENAL0013 (Other Identifier)

Details and patient eligibility

About

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Full description

This is a single arm prospective trial in patients with newly-diagnosed advanced renal cell cancer (RCC) who were scheduled for sunitinib therapy and utilized an extensive panel of quantitative metrics on baseline and interim FDG PET/CT to evaluate the predictive utility of each of these measurements.

The objectives were to evaluate the FDG PET/CT measurement parameters for prediction of prognosis after sunitinib therapy in patients with RCC using histopathologic (post-therapy nephrectomy) or clinical follow-up for validation.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- Measurable disease by RECIST criteria

Pathologic diagnosis of renal cell cancer
Advanced (stage IV) renal cell cancer
Karnofsky performance status of (KPS>70)
Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot complete a PET/CT scan.
Pregnant women.
Healthy volunteers.
Patients participating in other research protocols will be excluded from this study.
Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.